Real-World Effectiveness of CGRP Antagonists in Patients with Migraine and Cluster Headache: A Study Protocol

Authors

Suraj Malhan, DO/MS, Thomas Jefferson UniversityFollow
Areeba Nisar, MD, Thomas Jefferson UniversityFollow
Shreya Ghosh, BS, Thomas Jefferson UniversityFollow
Victor Wang, MD, Thomas Jefferson UniversityFollow
Nicole Spare, DO, Thomas Jefferson UniversityFollow
Michael Marmura, MD, Thomas Jefferson UniversityFollow
Hsiangkuo Yuan, MD, PhD, Thomas Jefferson UniversityFollow

Document Type

Poster

Publication Date

11-15-2024

Comments

Presented at the 2024 Scottsdale Headache Symposium.

Abstract

Background

Scientific Gap

Despite FDA approval of CGRP antagonists (gepant) in 2019, their realworld effectiveness and utilization patterns remain underexplored.

Study Objectives

- Evaluate the real-world usage and effectiveness of gepants for headache treatment based on survey responses.

- Assess patient-reported outcomes regarding acute and preventative average monthly use of gepants among current and past users.

• Preventative: Average monthly reduction in headache days, intensity, and daily functioning (>50% significant, <50% moderate, or no change).
• Acute: Consistency scaled as "never" to "always" of pain reduction, pain freedom, and function restoration at 2 hours; pain freedom at 24 hours.

- Identify any adverse effects with gepant use.

- Explore gepant responses based on situational use (menstruation, prodrome, aura).

- Compare the acute and preventive effectiveness of gepants to alternative treatments (triptans, DHE, mAb, Botox).

Recommended Citation

Malhan, DO/MS, Suraj; Nisar, MD, Areeba; Ghosh, BS, Shreya; Wang, MD, Victor; Spare, DO, Nicole; Marmura, MD, Michael; and Yuan, MD, PhD, Hsiangkuo, "Real-World Effectiveness of CGRP Antagonists in Patients with Migraine and Cluster Headache: A Study Protocol" (2024). Department of Jefferson Headache Center Papers and Presentations. Paper 21.
https://jdc.jefferson.edu/headache/21

Language

English